Management and Prognosis of Clear Cell Borderline Ovarian Tumor

Catherine Uzan, Uzan C, Marion Dufeu-Lefebvre, Dufeu-Lefebvre M, R. Fauvet, Fauvet R, Raffaele Fauvet, Gouy S, Sébastien Gouy, Sebastien Gouy, Duvillard P, Pierre Duvillard, Darai E, Emile Darai, Émile Daraï, Philippe Morice
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2012 · vol. 22(6) , pp. 993–999 · doi:10.1097/igc.0b013e3182534acf · PMID:22622950 · W2334957690
article OA: bronze CC0 ⤵ 4 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This paper describes the management and prognosis of clear cell borderline ovarian tumors, focusing on outcomes for patients diagnosed with this condition.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BackgroundThe clear cell borderline ovarian tumor (CCBOT) of the ovary is a rare tumor accounting for less than 1% of BOT. Fewer than 25 cases have been reported in the literature (including details on clinical management and outcomes). The aim of this study was to determine the prognosis of a series of CCBOTs collected in 2 reference centers.Patients and methodsThis was a retrospective review of patients with CCBOT treated or referred to our institutions. A centralized histological review by a reference pathologist and data on the clinical characteristics, management, and outcomes of patients were required for inclusion.ResultsTwelve patients were identified between 2000 and 2010. The median age of patients was 68 years (range, 36-83 years). Two had been treated conservatively and 9 radically (data unknown in 1). The tumor was unilateral in 11 cases. All patients had stage I disease. All cases were CCBOT with an adenofibromatous pattern. Stromal microinvasion or intraepithelial carcinoma was histologically associated in 2 and 3 cases, respectively. Four of the 12 patients had synchronous endometrial disorders (but no endometrioid carcinoma). No cases were histologically associated with endometriosis. Four patients were lost to follow-up. Among 8 other patients, after a median period of 28 months (range, 2-129 months), no recurrence had occurred (1 patient had died of another disease).ConclusionClear cell borderline ovarian tumor carries a good prognosis. All tumors are stage I; therefore, surgical staging is not necessary in most of the cases. Conservative treatment could be proposed to young patients, but uterine curettage would then be required in cases of uterine preservation.

My notes (saved in your browser only)

MeSH descriptors

Adenocarcinoma, Clear Cell Ovarian Neoplasms Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adult Aged Aged, 80 and over Female Humans Middle Aged Ovarian Neoplasms Ovarian Neoplasms Ovary Ovary Prognosis Retrospective Studies

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

Cited by (4)

References (20)

Cited by (4)

Source provenance

europepmc
last seen: 2026-08-07T06:07:27.085738+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:16:11.197438+00:00
License: CC0 · commercial use OK